Apo CIII is involved in inhibition of lipoprotein and hepatic lipases. It is thought to delay catabolism of triglyceride-rich particles. A defect in Apo CIII has been linked to hyperalphalipoproteinemia (HLAP), which causes increased levels of high density lipoprotein (HDL) (2). Recommended ...
Association of High-Density Lipoprotein Particles and High-Density Lipoprotein Apolipoprotein C-III Content With Cardiovascular Disease Risk According to Kidney Function: The Multi-Ethnic Study of Atherosclerosisdoi:10.1161/JAHA.119.013713Lamprea-Montealegre, Julio A....
There is growing evidence that apolipoprotein C-III (apoC-III), a small exchangeable apolipoprotein carried in the circulation by VLDL and HDL1, is a master regulator of plasma TG homeostasis and downregulation of its expression has a cardiovasculo-protective effect2. ApoC-III inhibits the activity...
Apolipoprotein AI-CIII-AIV gene cluster Lately, two novel susceptibility haplotypes i.e. P2-S2-X1 and P1-S2-X1 have been discovered in ApoAI-CIII-AIV gene cluster on chromosme 11q23, who confer approximately threefold higher risk of coronary heart disease in normal [6] as well as non-in...
Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis. 2003;168(1):81–9. 20. Tzeravini E, Tentolouris A, Eleftheriadou I, Chaviaras N, Kolovou G, Apos- tolidou-Kiouti F, et al. Comparison...
Apolipoprotein C-III (APO C-III) is a structural component of very-low-density and high-density lipoprotein particles and is an inhibitor of lipoprotein lipase. In a study of genetic variation of apolipoproteins in the Mayan population of the Yucatán peninsula, we observed a quantitative polymorp...
Apolipoprotein CIII (ApoCIII) not only serves as an inhibitor of triglyceride hydrolysis but also participates in diabetes-related pathological events such as hyperactivation of voltage-gated Ca2+ (CaV) channels in the pancreatic β cell. However, nothing is known about the molecular mechanisms...
Zheng, C. et al. Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. Eur. Heart J. 34, 615–624 (2013). Article CAS PubMed Google Scholar Gaidt, M. M. et al. Human monocytes engage an alternative inflammasome pathway. Immunity 44, 833–...
Preclinical studies suggest that a triglyceride (TG)-independent proinflammatory action of apolipoprotein C-III (apoCIII) exists. We aimed to investigate the relationship between circulating apoCIII levels and subclinical inflammation markers across diff
effects of olezarsen on apoC-III, fasting serum triglycerides, and other lipids/lipoproteins including apolipoprotein B-100 (apoB), total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and very low-density lipoprotein cholesterol (VLDL-C). ...